Article | Study Population | Experimental Conditions |
---|---|---|
[25] | Patients with impaired unilateral UL motor function due to stroke (n = 59) | Participants were randomly assigned to 3 groups: Occupational therapy + tDCS (n = 19) (A) VR instead of occupational therapy (n = 20) (B) VR therapy + tDCS (n = 20) |
[30] | Patients with stroke in the subacute stage (n = 15), and healthy participants (n = 15) | (C) All participants underwent 4 conditions in random order, in different consecutive days: (A) Active wrist exercise (B) VR wrist exercise (C) VR wrist exercise + tDCS (D) tDCS without wrist exercise |
[31] | Patients with impaired unilateral UL motor function due to unilateral stroke (n = 20) | Participants were randomly assigned to 2 groups: (A) VR + tDCS (n = 10) (B) VR + sham tDCS (n = 10) |
[29] | Patients with hemiplegia after stroke (n = 108) | Participants were randomly assigned to 2 groups: (A) VR + TMS (n = 55) (B) VR + sham TMS (n = 53) |
[28] | Patients with impaired motor function due to stroke (n = 3) | Participants were randomly assigned to 2 groups: (A) VR + TMS (n = 2) (B) VR + sham TMS (n = 1) |
[33] | Patient with severe left hemiparesis due to stroke (n = 1) | Participant underwent A-B-A conditions: (A) Motor rehabilitation (no VR nor tDCS) (n = 1) (B) Motor rehabilitation + VR + tDCS (n = 1) |
[32] | Patients with ischemic stroke (n = 40) | Participants were randomly assigned to 2 groups: (A) VR + tDCS (n = 20) (B) VR + sham tDCS (n = 20) |
[34] | Patients with spider phobia (n = 41), and healthy participants (n = 42) | Participants were randomly assigned to 2 groups: (A) VR + TMS (n = 40) (B) VR + sham TMS (n = 43) |
[35] | Patients with spider phobia (n = 41), and healthy participants (n = 42) | Participants were randomly assigned to 2 groups: (A) VR + TMS (n = 40) (C) VR + sham TMS (n = 43) |
[36] | Patients with PTSD (n = 12) | Participants were randomly assigned to 2 groups: (A) VR + tDCS (n = 6) (B) VR + sham tDCS (n = 6) |
[37] | Children patients with cerebral palsy (n = 12) | Participants were randomly assigned to 2 groups: (A) VR + tDCS (n = 6) (B) VR + sham tDCS (n = 6) |
[26] | Children patients with cerebral palsy (n = 12) | Participants were randomly assigned to 2 groups: (A) VR + tDCS (n = 6) (B) VR + sham tDCS (n = 6) |
[38] | Children patients with cerebral palsy (n = 20) | Participants were randomly assigned to 2 groups: (A) VR + tDCS (n = 10) (B) VR + sham tDCS (n = 10) |
[39] | Patients with SCI and NP (n = 39) | Participants were randomly assigned to 4 groups: (A) VR + tDCS (n = 10) (B) tDCS group (n = 10) (C) VR group (n = 9) (D) Placebo group (n = 10) |
[40] | Patients with SCI and NP (n = 18), patients with SCI without NP (n = 20), and healthy participants (n = 14) | Only SCI patients with NP underwent: VR + tDCS therapy (n = 18) |
[41] | Patient with primary-progressive MS (n = 1) | Participant underwent A-B conditions: (A) VR + tDCS (n = 1) (B) VR + sham tDCS (n = 1) |